SENS PubMed Publication Search
Effect of periodontal treatment on preclinical Alzheimer's disease-Results of a trial emulation approach
Christian Schwahn 1, Stefan Frenzel 2, Birte Holtfreter 3, Sandra Van der Auwera 2 4, Christiane Pink 3, Robin Bülow 5, Nele Friedrich 6 7, Henry Völzke 7 8, Reiner Biffar 1, Thomas Kocher 3, Hans Jörgen Grabe 2 4, Alzheimer's Disease Neuroimaging Initiative
Abstract:
Introduction: We investigated the relationship between periodontal treatment and pre-clinical Alzheimer's disease (AD).
Methods: In this quasi-experimental design, 177 periodontally treated patients from the "Greifswald Approach to Individualized Medicine" cohort, which used the same protocols as the population-based Study of Health in Pomerania TREND (SHIP-TREND), and 409 untreated subjects from SHIP-TREND were analyzed. Subjects were younger than 60 years at the magnetic resonance imaging examination, with a median observation period of 7.3 years. Imaging markers for brain atrophy in late-onset AD and brain aging were used as the outcomes.
Results: Robust to sensitivity analyses, periodontal treatment had a favorable effect on AD-related brain atrophy (-0.41; 95% confidence interval: -0.70 to -0.12; P = .0051), which corresponds to a shift from the 50th to the 37th percentile of the outcome distribution. For brain aging, the treatment effect was uncertain.
Methods: In this quasi-experimental design, 177 periodontally treated patients from the "Greifswald Approach to Individualized Medicine" cohort, which used the same protocols as the population-based Study of Health in Pomerania TREND (SHIP-TREND), and 409 untreated subjects from SHIP-TREND were analyzed. Subjects were younger than 60 years at the magnetic resonance imaging examination, with a median observation period of 7.3 years. Imaging markers for brain atrophy in late-onset AD and brain aging were used as the outcomes.
Results: Robust to sensitivity analyses, periodontal treatment had a favorable effect on AD-related brain atrophy (-0.41; 95% confidence interval: -0.70 to -0.12; P = .0051), which corresponds to a shift from the 50th to the 37th percentile of the outcome distribution. For brain aging, the treatment effect was uncertain.
